Stock of the Day

April 25, 2024

Solana (HSDT)

$1.69
-$0.03 (-1.5%)
Market Cap: $99.84M

About Solana

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.

Today's Trend

Solana Company (NASDAQ: HSDT) stock moved lower after the company’s Q3 2025 report and related disclosures. Investors are weighing big strategic wins around a digital-asset treasury and capital raises against a very large GAAP loss and significant derivative/financing charges.

  • Closed a >$500M partnership (Pantera Capital & Summer Capital) to fund a Solana token digital-asset treasury (DAT), increasing liquidity and creating a clear growth thesis tied to SOL exposure. Quiver Quant Summary
  • Capital markets actions: issued cash-exercise warrants (potential to raise up to $750M), launched an ATM program and approved a $100M buyback — all increase funding flexibility and signal management confidence. GlobeNewswire Release
  • Clinical progress: positive PoNS® data and a 510(k) submission for stroke label expansion provide upside for the original medtech business beyond the DAT story. Quiver Quant Summary
  • Operational beats: Q3 revenue of ~$0.7M (includes first-time staking rewards) and EPS (-$32.89) topped Street revenue/EPS estimates, but these are small relative to balance-sheet and non‑operating items. Yahoo Highlights
  • Large GAAP loss: Q3 net loss ≈ $352.8M driven by $545.7M loss on derivative liability valuation, $194.7M financing costs and related mark-to-market volatility — these non‑cash items massively pressured earnings and the balance sheet. GlobeNewswire Release
  • Digital asset volatility and costs: an unrealized digital-asset loss of $30.5M, higher operating expenses ($36M vs $3.9M prior) and a large derivative liability (~$625M on balance sheet) increase risk and dilution concerns. Quiver Quant Summary

Bottom line for investors: the strategic capital infusion and DAT initiatives are bullish for long-term SOL exposure, but near-term price reaction reflects heavy non‑cash losses, balance-sheet volatility and dilution risk from warrants/PIPE — factors driving the share decline.